Boston Scientific announced Joseph M. Fitzgerald as its new COO starting January 1, 2027, overseeing global operations and business units. The company will restructure into three reportable segments—Interventional Therapies, Rhythm Solutions, and MedSurg—to enhance decision-making and support strategic investment. This new structure aims to accelerate growth and keep the business close to customers and patients. The changes reflect Boston Scientific's expanding portfolio and focus on long-term growth priorities.
Boston Scientific's shares are trading at USD 42.17 on Pluang as of Oct 07, 2026, 17:11 WIB. The stock shows a slight 1-day decline of 0.05%, indicating stable investor sentiment despite the leadership change. Market activity on Pluang leans heavily toward buying, with 78% of orders favoring purchases at this time.
